Savara Inc. (SVRA)
| Bid | 2.8 |
| Market Cap | 499.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.48 |
| PE Ratio (ttm) | -6.03 |
| Forward PE | -5.92 |
| Analyst | Buy |
| Ask | 3.05 |
| Volume | 670,518 |
| Avg. Volume (20D) | 1,060,970 |
| Open | 2.90 |
| Previous Close | 3.01 |
| Day's Range | 2.86 - 3.00 |
| 52-Week Range | 2.25 - 5.34 |
| Beta | 0.52 |
About SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas....
Analyst Forecast
According to 6 analyst ratings, the average rating for SVRA stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 176.34% from the latest price.
Stock Forecasts
1 month ago · businesswire.com
Savara Announces Participation in the Leerink Global Healthcare ConferenceLANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its manageme...
